Zurcher Kantonalbank Zurich Cantonalbank grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 9.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,639 shares of the biopharmaceutical company's stock after buying an additional 2,117 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Intra-Cellular Therapies were worth $2,058,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. AlphaQuest LLC boosted its position in shares of Intra-Cellular Therapies by 49,687.5% during the 4th quarter. AlphaQuest LLC now owns 3,983 shares of the biopharmaceutical company's stock worth $333,000 after acquiring an additional 3,975 shares in the last quarter. Lisanti Capital Growth LLC raised its stake in Intra-Cellular Therapies by 24.9% during the 4th quarter. Lisanti Capital Growth LLC now owns 72,600 shares of the biopharmaceutical company's stock valued at $6,064,000 after acquiring an additional 14,485 shares during the last quarter. Candriam S.C.A. raised its stake in Intra-Cellular Therapies by 30.6% during the 4th quarter. Candriam S.C.A. now owns 214,320 shares of the biopharmaceutical company's stock valued at $17,900,000 after acquiring an additional 50,188 shares during the last quarter. Inceptionr LLC purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at approximately $1,034,000. Finally, Raymond James Financial Inc. purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at approximately $76,451,000. 92.33% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the company. StockNews.com began coverage on Intra-Cellular Therapies in a research note on Thursday. They set a "hold" rating for the company. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Canaccord Genuity Group cut Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their target price for the company from $119.00 to $132.00 in a report on Friday, January 31st. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $106.08.
View Our Latest Stock Analysis on ITCI
Intra-Cellular Therapies Stock Performance
Shares of ITCI traded up $0.07 during mid-day trading on Thursday, reaching $131.60. 921,853 shares of the company's stock traded hands, compared to its average volume of 1,331,124. The business's 50-day moving average price is $126.89 and its 200-day moving average price is $96.77. The stock has a market capitalization of $13.99 billion, a P/E ratio of -151.26 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.60.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Read More
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
